5-Year Safety Data From Upadacitinib Trials Reported 5-Year Safety Data From Upadacitinib Trials Reported

Upadacitinib trials in atopic dermatitis have included diverse patient groups with varying risk factors, according to Dr Christopher Bunick.MDedge News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Dermatology Source Type: news